Evidence map›Paper›PMID 28717075›Full record

ArticleInternal medicine (Tokyo, Japan)2017

Clinical Characteristics of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing Escherichia coli at a Tertiary Hospital.

Hiroki Namikawa, Koichi Yamada, Hiroki Fujimoto, Ken-Ichi Oinuma, Yoshihiro Tochino, Yasuhiko Takemoto, Yukihiro Kaneko, Taichi Shuto, Hiroshi Kakeya

Open access · diamondAbstract readComparative Study
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Measures used to assess the burden of ESBL-producingJAC-antimicrobial resistance · 2021
    Article
  8. Article
  9. Frontiers in cellular and infection microbiology · 2019
    Article
  10. Article
  11. The association of ESBLDrug target insights
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Hiroki NamikawaDepartment of Infection Control Science, Osaka City University, Graduate School of Medicine, Japan.
Koichi YamadaDepartment of Infection Control Science, Osaka City University, Graduate School of Medicine, Japan.
Hiroki FujimotoDepartment of Infection Control Science, Osaka City University, Graduate School of Medicine, Japan.
Ken-Ichi OinumaDepartment of Bacteriology, Osaka City University, Graduate School of Medicine, Japan.
Yoshihiro TochinoDepartment of Medical Education and General Practice, Osaka City University, Graduate School of Medicine, Japan.
Yasuhiko TakemotoDepartment of Medical Education and General Practice, Osaka City University, Graduate School of Medicine, Japan.
Yukihiro KanekoDepartment of Bacteriology, Osaka City University, Graduate School of Medicine, Japan.
Taichi ShutoDepartment of Medical Education and General Practice, Osaka City University, Graduate School of Medicine, Japan.
Hiroshi KakeyaDepartment of Infection Control Science, Osaka City University, Graduate School of Medicine, Japan.
Osaka City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective In recent years, infection caused by extended-spectrum beta-lactamase (ESBL)-producing organisms has become an important issue. However, comparative studies of the bacteremia caused by ESBL Enterobacteriaceae and non-ESBL Enterobacteriaceae are extremely rare in Japan. This study aimed to assess the risk factors and prognosis of patients with bacteremia due to ESBL Escherichia coli (E. coli). Methods The medical records of 31 patients with ESBL E. coli bacteremia and 98 patients with non-ESBL E. coli bacteremia who had been admitted to Osaka City University Hospital between January 2011 and June 2015 were retrospectively reviewed. The patient backgrounds, risk factors for infection, and prognosis were evaluated. Results The male-to-female ratio, mean age, underlying disease, leukocyte count, and C-reactive protein (CRP) level did not differ between the patients in the ESBL E. coli bacteremia and non-ESBL E. coli bacteremia groups. The mean Sequential Organ Failure Assessment (SOFA) score for patients with ESBL and non-ESBL E. coli bacteremia were 3.6 and 3.8, respectively. Further, the mortality did not differ between the two groups (9.7% vs 9.2%). However, the independent predictors associated with ESBL E. coli bacteremia according to a multivariate analysis were the use of immunosuppressive drugs or corticosteroids (p=0.048) and quinolones (p=0.005) prior to isolation. The mortality did not differ between the carbapenem and tazobactam/piperacillin (TAZ/PIPC) or cefmetazole (CMZ) groups for the patients with ESBL E. coli bacteremia. Conclusion Whenever we encountered patients with a history of immunosuppressive drug, corticosteroid, quinolone administration, it was necessary to perform antibiotic therapy while keeping the risk of ESBL E. coli in mind.

Indexed as

AdultAgedAnti-Bacterial AgentsBacteremiabeta-LactamasesCarbapenemsEscherichia coliEscherichia coli InfectionsFemaleHumansJapanMaleMiddle AgedPrognosisRetrospective StudiesRisk FactorsAnti-Bacterial Agentsbeta-LactamasesCarbapenemsbacteremiaEscherichia coliextended-spectrum beta-lactamaseimmunosuppressive drugquinolones

Identifiers

PMID28717075
PMCPMC5548672
OpenAlexW2734636404

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.